Although these new hypoglycemic drugs have satisfying effects in the treatment of DKD, some side effects, just as the urinary tract infection of SGLT2 inhibitor, the gastrointestinal reaction of incretin hormone, the hyperkalemia of MRAs, limit their application in some patients. The gene discussed is GCG; the disease is diabetic kidney disease.